Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own0.50% Shs Outstand175.40M Perf Week-2.01%
Market Cap14.28B Forward P/E- EPS next Y-0.31 Insider Trans-18.52% Shs Float174.54M Perf Month-8.16%
Income-174.60M PEG- EPS next Q-0.11 Inst Own100.00% Short Float3.94% Perf Quarter-7.53%
Sales1.20B P/S11.89 EPS this Y-253.70% Inst Trans1.56% Short Ratio5.27 Perf Half Y-8.84%
Book/sh16.03 P/B5.08 EPS next Y56.90% ROA-4.40% Target Price112.47 Perf Year-18.13%
Cash/sh4.15 P/C19.62 EPS next 5Y25.00% ROE-6.40% 52W Range78.42 - 102.06 Perf YTD-1.74%
Dividend- P/FCF- EPS past 5Y-51.20% ROI-17.50% 52W High-20.24% Beta1.88
Dividend %- Quick Ratio2.70 Sales past 5Y20.40% Gross Margin81.60% 52W Low3.80% ATR1.87
Employees2293 Current Ratio3.90 Sales Q/Q5.80% Oper. Margin-17.40% RSI (14)33.71 Volatility1.76% 2.13%
OptionableYes Debt/Eq0.24 EPS Q/Q91.80% Profit Margin-14.50% Rel Volume0.65 Prev Close81.46
ShortableYes LT Debt/Eq0.24 EarningsAug 02 AMC Payout- Avg Volume1.30M Price81.40
Recom2.00 SMA20-4.50% SMA50-8.11% SMA200-8.20% Volume846,164 Change-0.07%
Aug-17-17Initiated Evercore ISI Outperform $100
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Aug-05-16Reiterated Stifel Buy $107 → $113
Aug-05-16Reiterated Piper Jaffray Overweight $107 → $120
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Jan-20-16Initiated Credit Suisse Outperform
Jan-19-16Reiterated Wedbush Neutral $125 → $117
Nov-25-15Reiterated Oppenheimer Perform $119 → $115
Nov-18-15Initiated Goldman Buy
Oct-05-15Reiterated Wedbush Neutral $131 → $137
Aug-23-17 04:05PM  BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024 PR Newswire
11:38AM  3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical Inc. (BMRN) and Mondelez International Inc (MDLZ) InvestorPlace
Aug-21-17 08:30AM  Forbes Ranks BioMarin 12th Most Innovative Company in the World PR Newswire
Aug-17-17 10:05AM  Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst TheStreet.com
Aug-15-17 04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
08:30AM  BioMarin to Attend Upcoming Investor Conferences PR Newswire
Aug-12-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Aug-11-17 09:26PM  Edited Transcript of BMRN earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Aug-10-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Aug-09-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
06:00AM  20 Undervalued, Sustainable Stocks Morningstar
Aug-08-17 10:17AM  What Weighed On Biotechs Last Week? Barrons.com
Aug-07-17 07:24PM  BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024 PR Newswire
04:01PM  BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024 PR Newswire
Aug-04-17 01:43PM  BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter Motley Fool
Aug-03-17 09:38AM  BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates Zacks
Aug-02-17 10:02PM  BioMarin reports 2Q loss Associated Press
04:05PM  BioMarin Announces Second Quarter 2017 Financial Results PR Newswire
04:01PM  BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies PR Newswire
10:20AM  Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call ACCESSWIRE
Jul-31-17 04:01PM  BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET PR Newswire
09:34AM  Will Teladoc (TDOC) Pull Off a Surprise in Q2 Earnings? Zacks
08:41AM  Why Earnings Season Could Be Great for BioMarin (BMRN) Zacks
Jul-27-17 09:03AM  Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2? Zacks
Jul-24-17 02:27PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : July 24, 2017 Capital Cube
Jul-20-17 01:09PM  Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why Zacks
Jul-19-17 04:56PM  Sarepta & BioMarin Settle Patent Litigation on Exon Skipping Zacks
04:22PM  Sarepta Rockets On Consensus-Crushing Sales, Narrowing Losses Investor's Business Daily
01:45PM  Sarepta skips over a Duchenne patent battle with $35M settlement American City Business Journals
08:39AM  Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs Zacks
Jul-18-17 04:30PM  BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET PR Newswire
01:45PM  BioMarin snags cash as Sarepta skips Duchenne patent battle American City Business Journals
01:32PM  Sarepta, BioMarin Fall After Settling Patent Fight Barrons.com
08:30AM  Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation GlobeNewswire
Jul-14-17 01:09PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : July 14, 2017 Capital Cube
Jul-13-17 09:46AM  Biotech 2Q17: It's Mostly all Gravy Barrons.com
Jul-12-17 08:34AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : July 12, 2017 Capital Cube
Jul-11-17 04:43PM  Could This Biotech Win In Hemophilia With 'One And Done' Drug? Investor's Business Daily
03:30AM  BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year PR Newswire
Jul-10-17 09:07AM  What Analysts Recommend for BioMarin Pharmaceuticals Market Realist
07:38AM  BioMarin Expects These Drugs to Generate Steady Revenues Market Realist
Jul-07-17 05:08PM  A Barrage Of Biotech Updates Expected At ISTH Meeting Benzinga
04:37PM  Vimizim Could Significantly Drive BioMarins Revenue Growth Market Realist
03:05PM  Kuvan Could Boost BioMarins Revenue Growth in 2017 Market Realist
01:30PM  What to Expect from BioMarin Pharmaceuticals in 2017 Market Realist
Jul-05-17 08:12AM  Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More Zacks
Jul-03-17 10:11AM  BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase Zacks
Jun-30-17 09:10AM  BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU) PR Newswire
Jun-28-17 09:08AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : June 28, 2017 Capital Cube
Jun-27-17 02:36PM  Rare Diseases: Biotech's High Risk, Highest Reward Sub-Sector Forbes
Jun-26-17 03:27PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : June 26, 2017 Capital Cube
Jun-25-17 04:49PM  Quick Tips on Investing in the Pharmaceutical and Medical Device Industry GuruFocus.com
Jun-22-17 08:37AM  BioMarin (BMRN) in Focus: Stock Moves 7% Higher Zacks
Jun-16-17 08:38AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : June 16, 2017 Capital Cube
08:31AM  BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress PR Newswire
Jun-15-17 01:18PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : June 15, 2017 Capital Cube
Jun-14-17 09:45AM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-09-17 06:00AM  7 Reasons Why Prescription Drug Prices Are Extremely Expensive Motley Fool
Jun-08-17 08:20PM  The right to try: Terminally ill patients say trying experimental drugs offers hope. But is it just false hope? American City Business Journals
08:20PM  It takes billions of dollars to bring a new drug to the market; here are some of the reasons why American City Business Journals
09:47AM  BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound? Zacks
Jun-05-17 08:44AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : June 5, 2017 Capital Cube
Jun-02-17 11:14AM  BioMarin's (BMRN) Brineura Approved by European Commission Zacks
Jun-01-17 08:31AM  European Commission Approves Brineura (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Disease and Ultra-Rare Brain Disorder in Children PR Newswire
May-31-17 06:00AM  BioMarin to Attend Upcoming Investor Conference PR Newswire
May-24-17 09:17AM  Ultragenyx Receives Priority Review for rhGUS from FDA Zacks
May-12-17 04:20PM  Why Sangamo Therapeutics Inc. Jumped Higher Today Motley Fool
May-10-17 08:30AM  Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death Zacks
May-09-17 01:40PM  BioMarin Pharmaceutical Inc. Moves Toward Profitability Motley Fool
09:10AM  Edited Transcript of BMRN earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
09:00AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : May 9, 2017 Capital Cube
May-08-17 02:57PM  BioMarin: Is Profitability On The Horizon? Barrons.com
May-05-17 04:27PM  These Biotechs Are Grabbing Bullish Views In Wake Of Earnings Investor's Business Daily
10:30AM  BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up Zacks
May-04-17 04:46PM  BioMarin reports 1Q loss Associated Press
04:02PM  BioMarin Announces First Quarter 2017 Financial Results PR Newswire
10:55AM  Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call Accesswire
10:38AM  [$$] Did Gilead Cut Buybacks for Acquisition? Barrons.com
May-03-17 08:48AM  Why Earnings Season Could Be Great for BioMarin (BMRN) Zacks
May-02-17 08:30AM  BioMarin to Attend Two Upcoming Investor Conferences PR Newswire
Apr-28-17 07:13PM  BioMarin CEO says 'the system will have to determine' the... CNBC Videos
06:58PM  BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug CNBC
07:30AM  Today's Research Reports on Biotech Stocks to Watch: Pacific Biosciences of California and BioMarin Pharmaceutical Accesswire
Apr-27-17 07:29PM  BioMarin wins FDA approval for life-changing drug for kids with a $700,000-per-year cost American City Business Journals
06:17PM  BioMarin Prices Orphan Drug at $702,000, Promises Big Discounts Bloomberg
06:03PM  Biomarin sets high price for rare pediatric brain disease drug Reuters
04:36PM  Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year TheStreet.com
01:28PM  FDA Approves Brineura (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare Pediatric Brain Disorder in Children PR Newswire
11:34AM  BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again? Zacks
Apr-26-17 08:15AM  Blog Coverage Capricor Announces Positive Results from Trial for the Treatment of Duchenne Muscular Dystrophy Accesswire
Apr-25-17 04:05PM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : April 25, 2017 Capital Cube
01:44PM  Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates Benzinga
Apr-24-17 08:43AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : April 24, 2017 Capital Cube +5.71%
Apr-21-17 01:29PM  BioMarin Receives Positive CHMP Opinion in Europe for Brineura (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children PR Newswire
Apr-20-17 04:53PM  BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 at 4:30pm ET PR Newswire
Apr-19-17 07:57AM  Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed Zacks
Apr-17-17 09:20AM  5 Drug Stocks That Could Be Big Winners this Earnings Season Zacks
Apr-14-17 08:05AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : April 14, 2017 Capital Cube
Apr-13-17 04:18PM  The Hot Stock: Alexion Pharmaceuticals Climbs 3.3% Barrons.com
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davis George EricEVP, General CounselJun 23Option Exercise38.599,844379,88093,425Jun 27 08:46 PM
Davis George EricEVP, General CounselJun 23Sale96.609,844950,93083,581Jun 27 08:46 PM
Mueller BrianSVP, Corporate ControllerJun 22Option Exercise21.512,67157,45315,556Jun 23 05:39 PM
Mueller BrianSVP, Corporate ControllerJun 22Sale100.002,671267,10012,885Jun 23 05:39 PM
FUCHS HENRY JPresident, Worldwide R&DJun 19Option Exercise37.4660322,588137,025Jun 20 06:33 PM
FUCHS HENRY JPresident, Worldwide R&DJun 19Sale90.0060354,270136,422Jun 20 06:33 PM
LAWLIS V BRYANDirectorJun 16Option Exercise38.593,750144,71319,660Jun 20 06:31 PM
FUCHS HENRY JPresident, Worldwide R&DJun 16Option Exercise33.6514,397484,462150,819Jun 20 06:33 PM
LAWLIS V BRYANDirectorJun 16Sale90.003,750337,50015,910Jun 20 06:31 PM
FUCHS HENRY JPresident, Worldwide R&DJun 16Sale90.0014,3971,295,730136,422Jun 20 06:33 PM
Davis George EricEVP, General CounselJun 09Option Exercise23.549,239217,53083,581Jun 13 08:56 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 07Sale89.611,00489,96847,944Jun 09 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Option Exercise17.335,00086,650231,924Jun 06 08:34 PM
Davis George EricEVP, General CounselJun 05Sale91.049,471862,23074,342Jun 07 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Sale90.565,000452,800226,924Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 02Option Exercise17.335,00086,650238,564Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 02Sale89.705,000448,500233,564Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 01Option Exercise17.335,00086,650238,564Jun 05 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 01Sale87.535,000437,650233,564Jun 05 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Option Exercise17.337,423128,641240,987Jun 02 05:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Sale88.297,423655,377233,564Jun 02 05:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 24Option Exercise17.335,00086,650238,564May 26 05:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 24Sale88.385,000441,900233,564May 26 05:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Option Exercise17.335,00086,650238,564May 19 10:33 AM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Sale91.735,000458,650233,564May 19 10:33 AM
Davis George EricEVP, General CounselMay 16Option Exercise14.391,14616,49185,301May 17 06:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12Option Exercise17.335,00086,650243,496May 16 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12Sale89.235,000446,150238,496May 16 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise17.335,00086,650243,496May 09 01:19 PM
Mueller BrianSVP, Corporate ControllerMay 08Option Exercise21.512,60055,92616,068May 10 03:23 PM
Mueller BrianSVP, Corporate ControllerMay 08Sale91.877,482687,33413,468May 10 03:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale93.175,000465,850238,496May 09 01:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Option Exercise17.335,00086,650243,496May 09 01:19 PM
Davis George EricEVP, General CounselMay 05Option Exercise38.592,50096,47587,751May 09 01:21 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 05Option Exercise36.314,486162,87955,030May 09 01:23 PM
MEIER RICHARD ADirectorMay 05Option Exercise17.337,500129,97534,260May 09 01:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 05Sale99.004,486444,11451,532May 09 01:23 PM
Davis George EricEVP, General CounselMay 05Sale100.342,500250,85385,251May 09 01:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Sale99.005,000495,000238,496May 09 01:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 02Sale96.7430229,21551,532May 04 08:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Option Exercise17.335,00086,650243,194May 01 05:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Sale95.725,000478,600238,194May 01 05:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 25Option Exercise17.335,00086,650243,194Apr 27 06:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 25Sale94.005,000470,000238,194Apr 27 06:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 04Option Exercise14.393,00043,170238,194Apr 06 05:28 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 29Sale89.153,890346,79451,532Mar 31 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Option Exercise71.335,000356,650195,674Mar 17 06:27 PM
Davis George EricEVP, General CounselMar 16Sale91.962,238205,80673,729Mar 17 06:31 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 16Sale91.961,989182,90814,471Mar 17 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale91.965,000459,800190,674Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise17.335,00086,650211,364Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale91.425,000457,100206,364Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Option Exercise17.335,00086,650211,364Mar 15 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Sale92.685,000463,400206,364Mar 15 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Option Exercise17.335,00086,650211,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale91.095,000455,450206,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise17.336,000103,980212,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale90.186,000541,080206,364Mar 13 07:59 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 07Sale90.565,000452,80046,510Mar 08 07:31 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 06Sale93.322,303214,91620,761Mar 08 07:28 PM
Davis George EricEVP, General CounselMar 06Sale93.321,498139,79378,962Mar 08 07:24 PM
LAWLIS V BRYANDirectorMar 01Option Exercise17.337,500129,97521,360Mar 02 06:14 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 01Sale94.505,000472,50025,347Mar 02 06:20 PM
LAWLIS V BRYANDirectorMar 01Sale95.007,500712,50013,860Mar 02 06:14 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerFeb 28Option Exercise63.1030,0001,893,00060,347Mar 02 06:20 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerFeb 28Sale94.0030,0002,820,00030,347Mar 02 06:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 26Option Exercise17.335,00086,650175,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 26Sale84.005,000420,000170,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 25Option Exercise17.335,00086,650175,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 25Sale84.445,000422,200170,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 11Option Exercise17.334,00069,320174,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 11Sale89.844,000359,360170,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise17.334,00069,320174,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale91.314,000365,240170,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Option Exercise17.334,00069,320174,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale89.794,000359,160170,682Jan 10 04:53 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJan 09Sale90.005,000450,00018,100Jan 10 04:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Option Exercise17.334,00069,320174,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Sale87.194,000348,760170,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 30Option Exercise17.334,00069,320174,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 30Sale83.354,000333,400170,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Option Exercise17.334,00069,320174,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale83.844,000335,360170,682Jan 03 05:46 PM
FUCHS HENRY JPresident, Worldwide R&DNov 25Option Exercise26.4915,000397,350128,878Nov 29 08:34 PM
FUCHS HENRY JPresident, Worldwide R&DNov 25Sale87.4015,0001,310,988113,878Nov 29 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Option Exercise26.4969,7431,847,492240,425Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Sale85.6969,7435,976,515170,682Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 21Option Exercise26.4969,7441,847,519240,426Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 21Sale87.5669,7446,106,478170,682Nov 23 04:42 PM
Davis George EricEVP, General CounselNov 18Option Exercise38.595,000192,95075,798Nov 22 07:13 PM
Davis George EricEVP, General CounselNov 18Sale90.425,000452,10070,798Nov 22 07:13 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 16Option Exercise17.5441,670730,892365,038Nov 18 05:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 16Sale90.9741,6703,790,795323,368Nov 18 05:37 PM
LAWLIS V BRYANDirectorNov 09Option Exercise17.337,500129,97521,360Nov 14 01:59 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 09Sale90.6120,0001,812,20623,100Nov 14 02:02 PM
LAWLIS V BRYANDirectorNov 09Sale95.007,500712,50013,860Nov 14 01:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 08Option Exercise21.5170,0001,505,700393,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 08Sale82.8370,0005,797,806323,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 07Option Exercise21.5170,0001,505,700393,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 07Sale82.5270,0005,776,435323,368Nov 09 08:23 PM